Watch Video
Immunovaccine Inc. (TSX: IMV; OTCQX: IMMVF) develops cancer immunotherapies and infectious disease vaccines based on the Company’s DepoVax™ platform, a patented formulation that provides controlled and prolonged exposure of antigens and adjuvant to the immune system. Click here to learn about the growth strategy that makes Immunovaccine an attractive investment opportunity. Immunovaccine is advancing two DepoVax™-based clinical-stage cancer vaccines which have both been shown to be safe and capable of generating tumor-specific immune responses in Phase 1 clinical studies. Immunovaccine is currently conducting a Phase 2 study with its lead cancer vaccine therapy, DPX-Survivac, in recurrent lymphoma and is expected to enter additional Phase 2 clinical studies in ovarian cancer and glioblastoma.